EP01 — Import or Make in China

Entering China with a drug already approved in Europe or the US starts with one strategic choice: import the product, or manufacture it locally. This short film walks through both routes—NMPA import registration versus transfer to domestic production—and explains why many companies launch with imports, then localize as volume grows. It highlights the cost, supply-chain, and pricing advantages of going local, and positions CanalLotus Biotech as a single partner for registration, technology transfer, and GMP manufacturing inside China.